title: Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
abstract: OBJECTIVE
  To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.
  
  
  METHODS
  Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.
  
  
  RESULTS
  In total, 81% of the sample achieved symptom response and 48% symptom remission. The statistical analyses revealed early improvement within the first two treatment weeks in the SWN-K scale to be a significant predictor for symptomatic response. Concerning symptomatic remission the SF-36 and SWN-K baseline scores as well as SWN-K early improvement showed significant predictive value.
  
  
  CONCLUSIONS
  These results highlight the importance of the patient's self-perception and especially of early improvement of quality of life and subjective well-being for symptomatic treatment outcome.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany. rebecca.schennach-wolff@med.uni-muenchen.de
authors.forename: Rebecca
authors.initials: R
authors.lastname: Schennach-Wolff
authors.forename: Markus
authors.initials: M
authors.lastname: Jäger
authors.forename: Michael
authors.initials: M
authors.lastname: Obermeier
authors.forename: Max
authors.initials: M
authors.lastname: Schmauss
authors.forename: Gerd
authors.initials: G
authors.lastname: Laux
authors.forename: Herbert
authors.initials: H
authors.lastname: Pfeiffer
authors.forename: Dieter
authors.initials: D
authors.lastname: Naber
authors.forename: Lutz G
authors.initials: LG
authors.lastname: Schmidt
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Gaebel
authors.forename: Joachim
authors.initials: J
authors.lastname: Klosterkötter
authors.forename: Isabella
authors.initials: I
authors.lastname: Heuser
authors.forename: Kai-Uwe
authors.initials: KU
authors.lastname: Kühn
authors.forename: Matthias R
authors.initials: MR
authors.lastname: Lemke
authors.forename: Eckart
authors.initials: E
authors.lastname: Rüther
authors.forename: Stefan
authors.initials: S
authors.lastname: Klingberg
authors.forename: Markus
authors.initials: M
authors.lastname: Gastpar
authors.forename: Florian
authors.initials: F
authors.lastname: Seemüller
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
authors.forename: Michael
authors.initials: M
authors.lastname: Riedel
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology*; D011788:Quality of Life / Q000523:psychology*; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D014149:Tranquilizing Agents / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D014149:Tranquilizing Agents